One Put, One Call Option To Know About for Johnson & Johnson
Consistently, one of the more popular stocks people enter into their stock options watchlist at Stock Options Channel is Johnson & Johnson .
Thu Jul 24, 2014
Johnson & Johnson partners with Organovo to consider 3D-printing living tissue
The partnership centers around using bioprinted tissue to discover new drugs. The announcement comes ahead of Organovo's commercial launch later this year.
The New Zealand Herald
What's best for baby?
Sharon Dowling, research and development manager for leading company Johnson & Johnson , shares her advice.
Wed Jul 23, 2014
Johnson & Johnson Announces Quarterly Dividend for Third Quarter 2014
We embrace research and science - bringing innovative ideas, products and services to advance the health and well-being of people.
Tue Jul 22, 2014
The Motley Fool
3 Quotes From Johnson & Johnson's Conference Call You Need to Read
Here are three quotes from the call and some commentary about why they're so important.
Mon Jul 21, 2014
Johnson & Johnson (JNJ) Declares 70c Quarterly Dividend
The quarterly dividend is in line with the company's previous. The dividend is payable on Sept.
Wed Jul 16, 2014
Johnson & Johnson Given "Neutral" Rating at Zacks
's stock had its "neutral" rating reaffirmed by Zacks in a note issued to investors on Wednesday.
Johnson & Johnson Earnings: New Blockbuster Drug Olysio Lifts Sales But May Face Competition Soon
Johnson & Johnson recently released its second quarter results. While the company beat consensus estimates, its stock fell slightly due to a weaker-than-expected outlook for the second half of 2014.
J&J's Strong 2Q Led by Pharmaceuticals
Johnson & Johnson reported strong second-quarter results that exceeded both our and consensus expectations largely because of stronger-than-expected pharmaceutical sales.
Americans stock up on Tylenol, baby products
Americans have also been stocking up on anti-smoking aids, baby products, Aveeno skin care products and even Listerine mouthwash, according to the company.
Tue Jul 15, 2014
Johnson & Johnson Beats on EPS but Sags on a Technical Basis
The large-cap pharmaceutical company also beat on revenue and raised full-year guidance.
HAPPI/Household & PP Industry
Q2 Sales Rise at J&J
Johnson & Johnson posted a 9.1% increase in sales of $19.5 billion for the second quarter of 2014.
J&J beats forecasts, helped by new hepatitis C drug
Johnson & Johnson reported sharply better-than-expected quarterly revenue and earnings, fueled by strong sales of newer prescription drugs, including its Olysio treatment for hepatitis C. The diversified healthcare company on Tuesday said it earned $4.33 billion, or $1.51 per share, in the second quarter.
Tues., July 15: Hewlett-Packard Among Stocks to Watch
WSJ's Polya Lesova joins Simon Constable on the News Hub to discuss why investors are eyeing Hewlett-Packard, Reynolds American and Johnson & Johnson stock.
The Modesto Bee
J&J 2Q profit climbs 13 percent
The New Brunswick, New Jersey-based company said earnings increased to $4.33 billion, or $1.51 per share, from $3.83 billion, or $1.33 per share, in the same quarter a year ago.
Mon Jul 14, 2014
The Motley Fool
Earnings Preview: Abbott Laboratories and Johnson & Johnson
The health care sector in general, and biotech industry in particular, have now shrugged off their earlier first quarter dip.
Johnson & Johnson (JNJ) to Release Earnings on Tuesday
Johnson & Johnson is set to release its Q214 earnings data on Tuesday, July 15th.
Fri Jul 11, 2014
How Pharma Majors like Pfizer Inc. (PFE), Johnson & Johnson (JNJ) And ...
CNBC's Meg Tirrell reported on the popular "Squawk Box" program that patients suffering from Alzheimer disease in U.S and across the globe are assuming epidemic proportions with "5 million people currently have Alzheimer's in the united states" alone and has been estimated to have been the "sixth leading cause of death" in the country.
Johnson & Johnson Earnings Should Show Pharma Buisness To Remain Strong
Johnson & Johnson will report its Q2 2014 earnings on July 15. We expect no significant change in the intensity of the main trends driving the company's business .
First State Investigation Into Questionable Marketing Tactics Ends in ...
July 11th, 2014 - The state of Oregon launched an investigation into whether or not DePuy Orthopaedics, the manufacturer of now-recalled ASR metal-on-metal hip replacement devices , engaged in deceptive marketing practices by recommending the defective implants to residents of the state who were in need of hip replacement surgery.